Generation Bio Co. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on lease termination
Stock-based compensation expense
Depreciation and amortization expense
Amortization (accretion) of premium (discount) on marketable securities, net
Loss (gain) on sale of property and equipment
Other
Loss on impairment of property and equipment
Changes in operating assets and liabilities:
Collaboration receivable
Tenant receivable
Prepaid expenses and other current assets
Operating lease right-of-use assets
Other noncurrent assets
Accounts payable
Accrued expenses and other current liabilities
Deferred revenue
Operating lease liability
Deferred rent
Net cash used in operating activities

Cash flows from investing activities:
Purchases of property and equipment
Proceeds from sale of property and equipment
Purchases of marketable securities
Maturities of marketable securities
Net cash provided by (used in) investing activities
Cash flows from financing activities:
Proceeds from issuance of convertible preferred stock, net of issuance costs incurred and paid in current period
Proceeds from public offering of common stock, net of underwriting discounts and commissions
Payment of share issuance costs
Proceeds from issuance/sale of common stock
ModernaTX, Inc
ATM Offering
Total proceeds from issuance/sale of common stock
Proceeds from exercise of stock options and ESPP, net
Payments of deferred offering costs
Tax withholding payments related to net share settlements of restricted stock units
Net cash provided by financing activities

Net increase (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
Supplemental disclosure of noncash investing and financing information:
Lease liabilities arising from obtaining right-of-use assets
Purchases of property and equipment included in accounts payable and accrued expenses
Issuance costs included in accrued expenses
Unrealized gains (losses) on marketable securities
Offering costs included in accounts payable and accrued expenses
Conversion of convertible preferred stock to common stock

Comments